EGFR and neoplasm: For example, AR mechanisms were explored using circulating tumor DNA analysis in patients who were enrolled in the phase-III FLAURA study, which compared the efficacy of first-line osimertinib to first-generation EGFR-TKIs (gefitinib or erlotinib).